MedTrace Logo

Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)

NCT01201096 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2010-09-23

No results posted yet for this study

Summary

The purpose of this study is to show the tumor free long term survival of patients with isolated non-resectable liver metastases of neuroendocrine tumors after neo-adjuvant radio receptor treatment and following liver transplantation.

Conditions

Interventions

RADIATION

177Lutetium

two cycles of 177Lutetium radioreceptor therapy within two month

PROCEDURE

Liver transplantation

about 9 month after finishing the receptor therapy liver transplantation takes place

Sponsors & Collaborators

  • University of Jena

    lead OTHER

Principal Investigators

  • Christine Wurst, Dr. med. · Department of general-, visceral- and vascular surgery, University of Jena

  • Dieter Hörsch, Prof. Dr. med · Zentrum für neuroendokrine Tumore, Zentralklinik Bad Berka

  • Utz Settmacher, Prof. Dr. med. · Department of general-, visceral- and vascular surgery, University of Jena

  • R. B. Baum, Prof.Dr.med. · Center of neuroendocrine tumors, Zentralklinik Bad Berka

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2015-09-30
Completion
2018-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01201096 on ClinicalTrials.gov